The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study

被引：13

作者：

Almuradova, Elvina ^{[1
]}

Seyyar, Mustafa ^{[2
]}

Arak, Haci ^{[3
]}

Tamer, Fatih ^{[1
]}

Kefeli, Umut ^{[2
]}

Koca, Sinan ^{[4
]}

Sen, Erdem ^{[5
]}

Telli, Tugba Akin ^{[6
]}

Karatas, Fatih ^{[7
]}

Gokmen, Ivo ^{[8
]}

Turhal, Nazim Serdar ^{[9
]}

Sakalar, Teoman ^{[10
]}

Ayhan, Murat ^{[11
]}

Ekinci, Ferhat ^{[12
]}

Hafizoglu, Emre ^{[13
]}

Kahraman, Seda ^{[14
]}

Kesen, Oguzhan ^{[15
]}

Unal, Caglar ^{[16
]}

Alan, Ozkan ^{[17
]}

Celik, Serdar ^{[18
]}

Yekeduz, Emre ^{[15
]}

Omur, Ozgur ^{[19
]}

Gokmen, Erhan ^{[1
]}

机构：

[1] Ege Univ, Fac Med, Dept Med Oncol, Izmir, Turkiye

[2] Kocaeli Univ, Fac Med, Dept Med Oncol, Kocaeli, Turkiye

[3] Gaziantep Univ, Sahinbey Res & Applicat Hosp, Dept Med Oncol, Gaziantep, Turkiye

[4] Medeniyet Univ, Fac Med, Dept Med Oncol, Istanbul, Turkiye

[5] Canakkale Mehmet Akif Ersoy State Hosp, Dept Med Oncol, Canakkale, Turkiye

[6] Marmara Training & Res Hosp, Dept Med Oncol, Marmara, Turkiye

[7] Karabuk Univ, Dept Med Oncol, Karabuk, Turkiye

[8] Trakya Univ, Fac Med, Dept Med Oncol, Trakya, Turkiye

[9] Anatolian Hlth Ctr, Dept Med Oncol, Istanbul, Turkiye

[10] Kahramanmaras Necip Fazil City Hosp, Dept Med Oncol, Kahramanmaras, Turkiye

[11] Kartal Dr Lutfi Kirdar City Hosp, Dept Med Oncol, Istanbul, Turkiye

[12] Manisa Celal Bayar Univ, Dept Med Oncol, Manisa, Turkiye

[13] Ankara City Hosp, Dept Med Oncol, Ankara, Turkiye

[14] Antalya Training & Res Hosp, Dept Med Oncol, Antalya, Turkiye

[15] Adana City Hosp, Dept Med Oncol, Adana, Turkiye

[16] Gayrettepe Florence Nightingale Hosp, Dept Med Oncol, Istanbul, Turkiye

[17] Tekirdag Ismail F Cumaloglu City Hosp, Dept Med Oncol, Tekirdag, Turkiye

[18] Univ Hlth Sci Turkey, Izmir Bozyaka Educ & Res Hosp, Izmir Fac Med, Dept Urol, Izmir, Turkiye

[19] Ege Univ, Fac Med, Dept Nucl Med, Izmir, Turkiye

来源：

INTERNATIONAL JOURNAL OF CANCER | 2024年 / 154卷 / 04期

关键词：

lutetium-177; prostate cancer; PSMA-617; radioligand therapy;

D O I：

10.1002/ijc.34749

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Metastatic castration-resistant prostate cancer (mCRPC) remains a challenging condition to treat despite recent advancements. This retrospective study aimed to assess the activity and tolerability of Lutetium-177 (Lu-177) PSMA-617 radioligand therapy (RLT) in mCRPC patients across multiple cancer centers in Turkey. The study included 165 patients who received at least one cycle of Lu-177 PSMA-617 RLT, with the majority having bone metastases and undergone prior treatments. Prostate-specific antigen (PSA) levels were assessed before each treatment cycle, and the biochemical response was evaluated in accordance with the Prostate Cancer Work Group 3 Criteria. The PSA decline of >= 50% was classified as a response, while an increase of >= 25% in PSA levels was indicative of progressive disease. Neither response nor progression was considered as stable disease. The Lu-177 PSMA-617 RLT led to a significant PSA response, with 50.6% of patients achieving a >50% decrease in PSA levels. Median overall survival (OS) and progression-free survival were 13.5 and 8.2 months, respectively. Patients receiving Lu-177 PSMA-617 RLT in combination with androgen receptor pathway inhibitors (ARPIs) had a higher OS compared to those receiving Lu-177 PSMA-617 RLT alone (18.2 vs 12.3 months, P = .265). The treatment was generally well-tolerated, with manageable side effects such as anemia and thrombocytopenia. This study provides real-world evidence supporting the effectiveness and safety of Lu-177 PSMA-617 RLT in mCRPC patients, particularly when used in combination with ARPIs. These findings contribute to the growing body of evidence on the potential benefits of PSMA-targeted therapies in advanced prostate cancer.

引用

页码：692 / 700

页数：9

共 15 条

[1] Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial [J].

Annala, M. ;

Fu, S. ;

Bacon, J. V. W. ;

Sipola, J. ;

Iqbal, N. ;

Ferrario, C. ;

Ong, M. ;

Wadhwa, D. ;

Hotte, S. J. ;

Lo, G. ;

Tran, B. ;

Wood, L. A. ;

Gingerich, J. R. ;

North, S. A. ;

Pezaro, C. J. ;

Ruether, J. D. ;

Sridhar, S. S. ;

Kallio, H. M. L. ;

Khalaf, D. J. ;

Wong, A. ;

Beja, K. ;

Schonlau, E. ;

Taavitsainen, S. ;

Nykter, M. ;

Vandekerkhove, G. ;

Azad, A. A. ;

Wyatt, A. W. ;

Chi, K. N. .

ANNALS OF ONCOLOGY, 2021, 32 (07) :896-905

[2] PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, 2 trial [J].

Buteau, James P. ;

Martin, Andrew J. ;

Emmett, Louise ;

Iravani, Amir ;

Sandhu, Shahneen ;

Joshua, Anthony M. ;

Francis, Roslyn J. ;

Zhang, Alison Y. ;

Scott, Andrew M. ;

Lee, Sze-Ting ;

Azad, Arun A. ;

McJannett, Margaret M. ;

Stockler, Martin R. ;

Williams, Scott G. ;

Davis, Ian ;

Hofman, Michael S. .

LANCET ONCOLOGY, 2022, 23 (11) :1389-1397

[3] ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901) [J].

Emmett, Louise ;

Subramaniam, Shalini ;

Joshua, Anthony M. ;

Crumbaker, Megan ;

Martin, Andrew ;

Zhang, Alison Y. ;

Rana, Nisha ;

Langford, Ailsa ;

Mitchell, Jenna ;

Yip, Sonia ;

Francis, Roslyn ;

Hofman, Michael S. ;

Sandhu, Shahneen ;

Azad, Arun ;

Gedye, Craig ;

McJannett, Margaret ;

Stockler, Martin R. ;

Davis, Ian D. .

BJU INTERNATIONAL, 2021, 128 (05) :642-651

[4] TheraP: a randomized phase 2 trial of 177Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603) [J].

Hofman, Michael S. ;

Emmett, Louise ;

Violet, John ;

Zhang, Alison Y. ;

Lawrence, Nicola J. ;

Stockler, Martin ;

Francis, Roslyn J. ;

Iravani, Amir ;

Williams, Scott ;

Azad, Arun ;

Martin, Andrew ;

McJannett, Margaret ;

Davis, Ian D. .

BJU INTERNATIONAL, 2019, 124 :5-13

[5] EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT) [J].

Kratochwil, Clemens ;

Fendler, Wolfgang Peter ;

Eiber, Matthias ;

Baum, Richard ;

Bozkurt, Murat Fani ;

Czernin, Johannes ;

Delgado Bolton, Roberto C. ;

Ezziddin, Samer ;

Forrer, Flavio ;

Hicks, Rodney J. ;

Hope, Thomas A. ;

Kabasakal, Levant ;

Konijnenberg, Mark ;

Kopka, Klaus ;

Lassmann, Michael ;

Mottaghy, Felix M. ;

Oyen, Wim ;

Rahbar, Kambiz ;

Schoder, Heiko ;

Virgolini, Irene ;

Wester, Hans-Juergen ;

Bodei, Lisa ;

Fanti, Stefano ;

Haberkorn, Uwe ;

Herrmann, Ken .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (12) :2536-2544

[6] A randomized, double-blind, placebo (PBO)-controlled, phase 3b study of the efficacy and safety of continuing enzalutamide (ENZA) in chemotherapy-naive, metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with docetaxel (DOC) plus prednisolone (PDN) who have progressed on ENZA: PRESIDE. [J].

Merseburger, Axel S. ;

Attard, Gerhardt ;

Boysen, Gunther ;

Gourgioti, Georgia ;

Martins, Karla ;

Chowdhury, Simon .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)

[7]

Mirshahvalad Seyed Ali, 2023, Asia Ocean J Nucl Med Biol, V11, P23, DOI 10.22038/AOJNMB.2022.64964.1454

[8] EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent [J].

Mottet, Nicolas ;

van den Bergh, Roderick C. N. ;

Briers, Erik ;

Van den Broeck, Thomas ;

Cumberbatch, Marcus G. ;

De Santis, Maria ;

Fanti, Stefano ;

Fossati, Nicola ;

Gandaglia, Giorgio ;

Gillessen, Silke ;

Grivas, Nikos ;

Grummet, Jeremy ;

Henry, Ann M. ;

van der Kwast, Theodorus H. ;

Lam, Thomas B. ;

Lardas, Michael ;

Liew, Matthew ;

Mason, Malcolm D. ;

Moris, Lisa ;

Oprea-Lager, Daniela E. ;

van der Poel, Henk G. ;

Rouviere, Olivier ;

Schoots, Ivo G. ;

Tilki, Derya ;

Wiegel, Thomas ;

Willemse, Peter-Paul M. ;

Cornford, Philip .

EUROPEAN UROLOGY, 2021, 79 (02) :243-262

[9]

Olivier Timothee, 2023, Eur Urol, V84, P4, DOI [10.1016/j.eururo.2022.08.022, 10.1016/j.eururo.2022.08.022]

[10] Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer [J].

Sartor, Oliver ;

de Bono, Johann ;

Chi, Kim N. ;

Fizazi, Karim ;

Herrmann, Ken ;

Rahbar, Kambiz ;

Tagawa, Scott T. ;

Nordquist, Luke T. ;

Vaishampayan, Nitin ;

El-Haddad, Ghassan ;

Park, Chandler H. ;

Beer, Tomasz M. ;

Armour, Alison ;

Perez-Contreras, Wendy J. ;

DeSilvio, Michelle ;

Kpamegan, Euloge ;

Gericke, Germo ;

Messmann, Richard A. ;

Morris, Michael J. ;

Krause, Bernd J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (12) :1091-1103

← 1 2 →